Appearance of ANCA - Associated vasculitis under tumor necrosis factor-alpha inhibitors treatment

American Journal of Case Reports

Volumn 14, Issue , 2013, Pages 80-82

  Reitblat, Tatiana ^a   Reitblat, Olga ^a  

^a BARZILAI MEDICAL CENTER   (Israel)

Author keywords

Psoriatic arthritis; Rheumatoid arthritis; Systemic vasculitis; Tumor necrosing factor alpha inhibitors

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ABNORMAL LABORATORY RESULT; ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; ASTHMA; CASE REPORT; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; NOSE POLYP; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 84875476394     PISSN: None     EISSN: 19415923     Source Type: Journal    
DOI: 10.12659/AJCR.883841     Document Type: Article

References (15)

1. Alonso-Ruiz A, Pijoan JI, Ansuategui E et al: Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord, 2008; 9: 52.
2. Williams VL, Cohen PR: TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol, 2011; 50(5): 619-25
3. Fujikawa K, Kawakami A, Hayashi T et al: Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol, 2010; 20(1): 86-89.
4. Simms R, Kipgen D, Dahill S et al: ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis, 2008; 51(3): e11-14.
5. Nakano M, Ueno M, Nishi S et al: Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol, 1998; 50(3): 154-60.
6. Stokes MB, Foster K, Markowitz GS et al: Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant, 2005; 20(7): 1400-6.
7. De Bandt M, Saint-Marcoux B: Tumour necrosis factor alpha blockade and the risk of vasculitis. Ann Rheum Dis, 2006; 65(11): 1534-35.
8. Chewoolkar V, Bichile LS, Jain N, Raj P: Psoriatic arthritis with ANCApositive vasculitis: a rare association. Int J Rheum Dis, 2008; 11(2): 192-94.
9. Wong SS, Marks R: Cutaneous vasculitis in psoriasis. Acta Derm Venerrol, 1994; 74: 57-60.
10. De Bandt M, Meyer O, Haim T, Kahn MF: Antineutrophilic cytoplasmic antibody in Rheumatoid arthritis. Br J Rheumatol, 1996; 35: 38-43.
11. Ramos-Casals M, Brito-Zeron P, Minoz S et al: Autoimmune Diseases Induced by TNF-Targeted Therapies. Analysis of 233 Cases. Medicine, 2007; 86: 242-51.
12. Curtis JR, Jain A, Askling J et al: A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum, 2010; 40(1): 2-14.e1.
13. Mcilwain L, Carter JD, Bin-Sagheer S et al: Hypersensetivity vasculitis with leukocytoclastic vasculitis secondary to ifliximab. J Clin Gastroenterol, 2003; 36: 411-13.
14. Jarreff SJ, Cunnane G, Canaghan PG et al: Anti-tumor necrosis factoralpha therapy-induced vasculitis: case series. J Rheumatol, 2003; 30: 2287-91.
15. Guillevin L, Mouthon L: Tumor necrosis factor-alpha blocade and the risk of vasculitis. J Rheumatol, 2004; 31: 1885-87